Viatris Developed Markets — Other revenues remained flat by 0.0% to $9.53M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.1%, from $8.00M to $9.53M. Over 3 years (FY 2022 to FY 2025), Developed Markets — Other revenues shows an upward trend with a 20.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates successful monetization of intellectual property or secondary business capabilities, diversifying the revenue base.
Revenue generated within the Developed Markets segment that is not derived from primary product sales, such as royalties...
Often labeled as 'Other Revenue' or 'Service Revenue' in segment reporting for diversified pharmaceutical firms.
vtrs_segment_developed_markets_other_revenues| FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|
| Value | $21.80M | $26.10M | $32.00M | $38.10M |
| YoY Change | — | +19.7% | +22.6% | +19.1% |